MedTrace Logo

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

NCT00759291 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-02-21

Study results available
· View outcomes & findings →

Summary

This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic syndrome.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

acipimox

250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit

DRUG

Placebo

1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Joshua A. Beckman, M.D. · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-01
Primary Completion
2017-12-01
Completion
2017-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00759291 on ClinicalTrials.gov